These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3034424)

  • 1. High-dose (200 mg/m2) cisplatin-induced neurotoxicity in primary advanced ovarian cancer patients.
    Panici PB; Greggi S; Scambia G; Di Roberto P; Iacobelli S; Mancuso S
    Cancer Treat Rep; 1987 Jun; 71(6):669-70. PubMed ID: 3034424
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral neuropathy secondary to cis-Dichlorodiammino-platinum (II) (Platinol). Treatment for advanced ovarian cancer.
    Marin AC; Rierson B
    Ariz Med; 1979 Dec; 36(12):898-9. PubMed ID: 229809
    [No Abstract]   [Full Text] [Related]  

  • 4. High-dose cisplatin-related peripheral neuropathy.
    Ostchega Y; Donohue M; Fox N
    Cancer Nurs; 1988 Feb; 11(1):23-32. PubMed ID: 2834044
    [No Abstract]   [Full Text] [Related]  

  • 5. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.
    Argyriou AA; Chroni E; Koutras A; Ellul J; Papapetropoulos S; Katsoulas G; Iconomou G; Kalofonos HP
    Neurology; 2005 Jan; 64(1):26-31. PubMed ID: 15642899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cisplatin polyneuropathy].
    Beghi E; Bogliun G; Crespi V; Delodovici ML; Landoni F
    Riv Neurobiol; 1984; 30(2-3):431-7. PubMed ID: 6100526
    [No Abstract]   [Full Text] [Related]  

  • 9. [Erythropoietin and cisplatin-induced neuropathies in cancer patients].
    Mangiameli A; Spina S; Iannetti E; Catalano D; Spadaro D; Trovato GM
    Clin Ter; 2002; 153(3):177-80. PubMed ID: 12161978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer.
    Roberts JA; Jenison EL; Kim K; Clarke-Pearson D; Langleben A
    Gynecol Oncol; 1997 Nov; 67(2):172-7. PubMed ID: 9367703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists.
    Calhoun EA; Bennett CL; Peeples PA; Lurain JR; Roland PY; Weinstein JM; Fishman DA
    Gynecol Oncol; 1998 Dec; 71(3):369-75. PubMed ID: 9887233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy.
    Vogl SE; Pagano M; Davis TE; Einhorn N; Tunca JC; Kaplan BH; Arseneau JC
    Cancer Treat Rep; 1982 Jun; 66(6):1285-90. PubMed ID: 6282454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
    Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
    Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
    Malmström H; Rasmussen S; Simonsen E
    Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A pilot trial of high dose CEP (cyclophosphamide, epirubicin, cis-platinum) therapy in patients with advanced and recurrent ovarian cancer].
    Hiura M; Ogawa M; Nozawa S; Kudo R; Kuwabara Y; Takahashi T; Takayama M; Tateno M; Ohashi Y; Yakushiji M
    Gan To Kagaku Ryoho; 2000 Apr; 27(4):585-91. PubMed ID: 10791001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.
    Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C
    Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.
    Connelly E; Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 1996 Aug; 62(2):166-8. PubMed ID: 8751544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study on the relation between cisplatin neuropathy and vitamin E.
    Bove L; Picardo M; Maresca V; Jandolo B; Pace A
    J Exp Clin Cancer Res; 2001 Jun; 20(2):277-80. PubMed ID: 11484987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.